Search Results | Cancer Research | American Association for Cancer Research

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Abstract CT243: A phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced renal cell carcinoma (RCC) who progressed on PD-1/L1 and VEGF inhibitors

Hans Hammers, Toni Choueiri, Elizabeth Plimack, Brian Rini, Robert Motzer, Lina Yin, Rodolfo Perini, Jaqueline Willemann-Rogerio, Laurence Albiges

Cancer Res (2021) 81 (13_Supplement): CT243.

DOI: https://doi.org/10.1158/1538-7445.AM2021-CT243

Published: 01 July 2021

View article

Journal Articles

Abstract 4106: Outcomes of combined ipilimumab and nivolumab therapy following progression on nivolumab monotherapy in renal cell carcinoma: A retrospective cohort study

Roy M. Elias, Nirmish Singla, Isaac A. Bowman, Payal Kapur, Raquibul Hannan, Hans Hammers, James Brugarolas

Cancer Res (2019) 79 (13_Supplement): 4106.

DOI: https://doi.org/10.1158/1538-7445.AM2019-4106

Published: 01 July 2019

View article

Journal Articles

Abstract 5084: Overcoming the resistance to anti-angiogenic therapy: Itraconazole blocks blood vessel maturation and synergizes with anti-VEGF therapy.

Chenglai Fu, Stephanie Gerber, Richmond Castillo, Anita van der Zwan, Sushant Kachhap, Hans Hammers

Cancer Res (2013) 73 (8_Supplement): 5084.

DOI: https://doi.org/10.1158/1538-7445.AM2013-5084

Published: 15 April 2013

View article

Journal Articles

Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment

John T. Isaacs, Lizamma Antony, Susan L. Dalrymple, W. Nathaniel Brennen, Stephanie Gerber, Hans Hammers, Michel Wissing, Sushant Kachhap, Jun Luo, Li Xing, Per Björk, Anders Olsson, Anders Björk, Tomas Leanderson

Cancer Res (2013) 73 (4): 1386–1399.

DOI: https://doi.org/10.1158/0008-5472.CAN-12-2730

Published: 14 February 2013

View article

Includes: Supplementary data

Journal Articles

Abstract 1913: Epithelial mesenchymal transition: A mechanism of resistance to VEGF pathway inhibition in genitourinary cancers

Chenglai Fu, Stephanie Gerber, Susanna Van Den Berg, Frans Steenwinkel, Huub Kant, Whei Moriarty, Daniel Keizman, Luigi Marchionni, Michael Carducci, Georges Netto, Sushant Kachhap, Hans Hammers

Cancer Res (2012) 72 (8_Supplement): 1913.

DOI: https://doi.org/10.1158/1538-7445.AM2012-1913

Published: 15 April 2012

View article

Journal Articles

Abstract 2049: Preclinical profile of AMG900 in combination with HDACIs in prostate cancer

Channing Paller, Michel Wissing, Eugene Kim, Hans Hammers, Charles Rudin, Michael Carducci, Sushant Kachhap

Cancer Res (2012) 72 (8_Supplement): 2049.

DOI: https://doi.org/10.1158/1538-7445.AM2012-2049

Published: 15 April 2012

View article

Journal Articles

Abstract 5281: Regulation of tumor growth and angiogenesis by Wilms tumor 1(WT1)

Varalakshmi Katuri, Stephanie Gerber, Xiaofei Qiu, Gregory McCarty, Hans Hammers, Elizabeth Montgomery, David M. Loeb

Cancer Res (2012) 72 (8_Supplement): 5281.

DOI: https://doi.org/10.1158/1538-7445.AM2012-5281

Published: 15 April 2012

View article

Journal Articles

Abstract 4701: Tasquinimod suppresses the adaptive stress response within sites of prostate cancer via disrupting zinc-dependent Histone Deacetylase 4 signaling.

Lizamma Antony, Susan Dalrymple, Stephanie Gerber, Hans Hammers, Sushant Kachhap, Per Bjork, Anders Olsson, Tomas Leanderson, John T. Isaacs

Cancer Res (2012) 72 (8_Supplement): 4701.

DOI: https://doi.org/10.1158/1538-7445.AM2012-4701

Published: 15 April 2012

View article

Journal Articles

Abstract 2557: Preclinical synergy of Plk1 inhibitors and HDACIs

Channing J. Paller, Michel D. Wissing, Nadine S. Rosmus, Hans Hammers, Charles M. Rudin, Michael A. Carducci, Sushant K. Kachhap

Cancer Res (2011) 71 (8_Supplement): 2557.

DOI: https://doi.org/10.1158/1538-7445.AM2011-2557

Published: 15 April 2011

View article

Journal Articles

Abstract 5414: Targeting prostate cancer through a combination of Polo-like kinase inhibitors and histone deacetylase inhibitors

Michel D. Wissing, Nadine Rosmus, Matthew Gonzalez, Hans Hammers, Michael A. Carducci, Sushant K. Kachhap

Cancer Res (2010) 70 (8_Supplement): 5414.

DOI: https://doi.org/10.1158/1538-7445.AM10-5414

Published: 15 April 2010

View article

Journal Articles

Abstract #150: The antiangiogenic tyrosine kinase inhibitor (TKI) sunitinib has direct antitumor activity on renal and colorectal cancer cells in vitro at intratumoral concentrations achieved in mice

Kristy Gotink, Michelle Rudek, Henk Broxterman, Janneke Jaspers, Hans Hammers, Godefridus Peters, Roberto Pili, Henk Verheul

Cancer Res (2009) 69 (9_Supplement): 150.

Published: 01 May 2009

View article

Journal Articles

Abstract #2834: Digoxin and other cardiac glycosides inhibit HIF-1\#945; synthesis and block tumor growth

Huafeng Zhang, David Qian, Yee Sun Tan, KangAe Lee, Ping Gao, Yunzhao Ren, Sergio Rey, Hans Hammers, Daniel Chang, Roberto Pili, Chi Dang, Jun Liu, Gregg Semenza

Cancer Res (2009) 69 (9_Supplement): 2834.

Published: 01 May 2009

View article

Journal Articles

Abstract #2328: Preclinical testing of a vascular disrupting agent in combination to an mTOR inhibitor in renal cell carcinoma models.

Preeti Shah, Georges Ndikuyeze, Hans Hammers, Roberto Pili

Cancer Res (2009) 69 (9_Supplement): 2328.

Published: 01 May 2009

View article

Journal Articles

From bedside to the bench: tumor microenvironment is responsible for the acquired resistance to tyrosine kinase inhibitors in renal cell carcinoma

Hans Hammers, Brenda Salumbides, Li Shen, Silvia Paesante, Michelle Rudek, Henk Verheul, Roberto Pili

Cancer Res (2008) 68 (9_Supplement): 366.

Published: 01 May 2008

View article

Journal Articles

Combination of the VEGF receptor tyrosine kinase sunitinib and the mTOR inhibitor rapamycin leads to tumor regression in the RENCA model

Hans Hammers, Silvia Paesante, Li Shen, Michelle Rudek, Roberto Pili

Cancer Res (2008) 68 (9_Supplement): 1104.

Published: 01 May 2008

View article

Journal Articles

LP261, a new microtubules inhibitor, induces disruption of endothelial cell sprouting and modulates the expression of the hypoxia-inducible factor 1 alpha

Silvia Paesante, Hans Hammers, Li Shen, William Moore, Roberto Pili

Cancer Res (2008) 68 (9_Supplement): 1405.

Published: 01 May 2008

View article

Journal Articles

An in-vitro model for vascular regression with anti-angiogenic treatments

Hans Hammers, Roberto Pili

Cancer Res (2007) 67 (9_Supplement): 3831.

Published: 01 May 2007

View article

NARROW

Abstract CT243: A phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced renal cell carcinoma (RCC) who progressed on PD-1/L1 and VEGF inhibitors

Abstract 4106: Outcomes of combined ipilimumab and nivolumab therapy following progression on nivolumab monotherapy in renal cell carcinoma: A retrospective cohort study

Abstract 5084: Overcoming the resistance to anti-angiogenic therapy: Itraconazole blocks blood vessel maturation and synergizes with anti-VEGF therapy.

Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment

Abstract 1913: Epithelial mesenchymal transition: A mechanism of resistance to VEGF pathway inhibition in genitourinary cancers

Abstract 2049: Preclinical profile of AMG900 in combination with HDACIs in prostate cancer

Abstract 5281: Regulation of tumor growth and angiogenesis by Wilms tumor 1(WT1)

Abstract 4701: Tasquinimod suppresses the adaptive stress response within sites of prostate cancer via disrupting zinc-dependent Histone Deacetylase 4 signaling.

Abstract 2557: Preclinical synergy of Plk1 inhibitors and HDACIs

Abstract 5414: Targeting prostate cancer through a combination of Polo-like kinase inhibitors and histone deacetylase inhibitors

Abstract #150: The antiangiogenic tyrosine kinase inhibitor (TKI) sunitinib has direct antitumor activity on renal and colorectal cancer cells in vitro at intratumoral concentrations achieved in mice

Abstract #2834: Digoxin and other cardiac glycosides inhibit HIF-1\#945; synthesis and block tumor growth

Abstract #2328: Preclinical testing of a vascular disrupting agent in combination to an mTOR inhibitor in renal cell carcinoma models.

From bedside to the bench: tumor microenvironment is responsible for the acquired resistance to tyrosine kinase inhibitors in renal cell carcinoma

Combination of the VEGF receptor tyrosine kinase sunitinib and the mTOR inhibitor rapamycin leads to tumor regression in the RENCA model

LP261, a new microtubules inhibitor, induces disruption of endothelial cell sprouting and modulates the expression of the hypoxia-inducible factor 1 alpha

An in-vitro model for vascular regression with anti-angiogenic treatments

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only